丨 2026年8月11日星期二丨 NO.1百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作 8月10日,百济神州宣布与全球专注癌症药物研发的生物科技公司Revolution Medicines达成一项多方面合作协议,涵盖临床联合开发与区域商业化授权两大核心板块,旨在加速RAS驱动型癌症的创新疗法研发与市场落地。 点评:本次合作使百济神州有机会评估公司肿瘤产品...
Source Link丨 2026年8月11日星期二丨 NO.1百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作 8月10日,百济神州宣布与全球专注癌症药物研发的生物科技公司Revolution Medicines达成一项多方面合作协议,涵盖临床联合开发与区域商业化授权两大核心板块,旨在加速RAS驱动型癌症的创新疗法研发与市场落地。 点评:本次合作使百济神州有机会评估公司肿瘤产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.